Company intelligence / Profile preview
SASPiPhi
Cambridge, England, United Kingdomsaspiphi.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
SASPiPhi is developing the SASPject antimicrobial platform, which uses engineered bacteriophages to deliver a gene encoding a toxic protein (SASP) to target bacteria, resulting in bacterial death. The technology aims to overcome antibacterial resistance.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Engineered bacteriophages
- Industry
- Biotech
02
Drug pipeline
12 assets11 more assets in the full pipeline.
Beyond the preview
Go deeper on SASPiPhi.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SASPiPhi.